COVE R S TORY
Forced to prioritise limited isolation spaces based on individual risk-assessments, which patient presents the most risk and is therefore moved to an isolation room? Someone infected with SARS-CoV-2, a severe bacterial infection or a stubborn multi- drug resistant organism? How you choose which patient remains unclear. By using Rediroom, the isolation capacity of the hospital increases and in turn, some of the pressure is released as patients infected by traditional HCAIs can be isolated. In 2020, University Hospitals of Derby and Burton NHS Foundation Trust increased their overall isolation capacity by 12% – a noteworthy success captured by BBC News.7
Making the most of our money While the demand for increasing capacity is centre of attention, all eyes are on the cost of implementing single-patient isolation rooms across all NHS hospitals. Changes to infection prevention practice are more likely to be accepted if they’re supported by cost-effective analysis. An effective product should be able to help reduce the £2.9 billion the NHS is currently paying out for HCAIs. In a 2021 study, a financial model was produced to determine if Rediroom could be a cost-effective intervention for the NHS.8 Using published data which looked at the rates of HCAIs in UK hospitals, the authors
tracked the impact of temporary isolation rooms against cost per Life Year Gained. This measure calculates the cost of a particular piece of equipment for each year of life gained for patients.
The researchers concluded that Rediroom is likely to be cost-effective in the NHS, as it was found to have an estimated cost of just £5,829 per LYG. For reference, NICE tends to fund programmes that cost below £13,000 per life-year gained.
Along with its proven ability to increase isolation capacity and cost-effectiveness, Rediroom’s innovative design has landed it with multiple awards around the globe, including Australian Good Design Award Gold Accolade for ‘Engineering Design’ and ‘Product Design – Medical and Scientific’. Isolation demand has been dragged into global focus in the past year. The evidence clearly shows that patient isolation is an essential and effective component in
preventing and controlling infection. Yet most organisations are unable to meet the demand for capacity that the current climate calls for. As demand continues to fluctuate, there is a growing need for a flexible solution that can protect both patients and staff in healthcare. To find out more, speak to your GAMA Healthcare Area Manager or visit:
www.rediroom.com.
References 1 Cox et al. J Hosp Infect. 1995 Feb;29(2):87-106. 2 Guest et al. BMJ Open. 2020;10(1):1-11. 3
www.nice.org.uk/guidance/cg139/chapter/ introduction [Accessed 10 Nov 2021]
4
https://researchbriefings.files.parliament.uk/ documents/CDP-2018-0116/CDP-2018-0116.pdf [Accessed 10 Nov 21]
5 Mitchell BG et al. Infect Dis Heal. 2017;22(3):129-135. 6 Mitchell BG et al. Am J Infect Control. 2017. 7
www.bbc.co.uk/news/av/health-54910619 8 Graves N et al. J Hosp Infect. 2021 Oct; 116:21-28.
The Maylands Building, Maylands Avenue,
Hemel Hempstead Industrial Estate, Hemel Hempstead, Hertfordshire HP2 7TG
T: +44 (0)20 7993 0030 E:
info@gamahealthcare.com
www.gamahealthcare.com
DECEMBER 2021
WWW.CLINICALSERVICESJOURNAL.COM l 5
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
